The Role of 18F-fluorodeoxyglucose Positron Emission Tomography in Thyroid Neoplasms

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2011 Mar 8

PMID 21378078

Citations 7

Authors

Brian Hung-Hin Lang

Tsz Ting Law

Affiliations

Soon will be listed here.

Abstract

(18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has established itself as an important imaging modality in many oncological and nononcological specialties and, as a consequence, it is increasingly being used in clinical practice. Since the first report of FDG being taken up by metastatic differentiated thyroid carcinoma (DTC) cells >20 years ago, various groups of investigators have explored the potential role of FDG-PET scanning in patients with benign and malignant thyroid neoplasms. With the increasing demand for FDG-PET scanning, clinicians are faced with the challenge of managing an increasing number of FDG-PET-detected thyroid incidentalomas because their significance remains unclear. The aims of this review are to address some of these issues, specifically, the clinical significance of FDG-PET-detected thyroid incidentalomas, the ability of FDG-PET to characterize thyroid nodules, especially those with indeterminate fine needle aspiration cytology results, and the role of FDG-PET in patients with confirmed primary DTC and with suspected recurrent DTC, by reviewing the current literature.

Citing Articles

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review.

Buczynska A, Kosciuszko M, Kretowski A, Poplawska-Kita A Front Pharmacol. 2024; 15:1323083.

PMID: 38292938 PMC: 10824900. DOI: 10.3389/fphar.2024.1323083.

A Multimodal and Pathological Analysis of a Renal Cell Carcinoma Metastasis to the Thyroid Gland 11 Years Post Nephrectomy.

Geisbush T, Dymon Z, Gabriel M, Yedavalli V J Radiol Case Rep. 2019; 13(4):1-9.

PMID: 31565176 PMC: 6743643. DOI: 10.3941/jrcr.v13i4.3497.

Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.

Wassermann J, Bernier M, Spano J, Lepoutre-Lussey C, Buffet C, Simon J Oncologist. 2015; 21(1):50-8.

PMID: 26675742 PMC: 4709201. DOI: 10.1634/theoncologist.2015-0107.

The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials.

Pak K, Cheon G, Kang K, Kim S, Kim I, Edmund Kim E J Korean Med Sci. 2014; 29(6):811-7.

PMID: 24932083 PMC: 4055815. DOI: 10.3346/jkms.2014.29.6.811.

New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review.

Wong K, Lang B J Thyroid Res. 2013; 2012:818204.

PMID: 23320248 PMC: 3540819. DOI: 10.1155/2012/818204.

References

Robbins R, Wan Q, Grewal R, Reibke R, Gonen M, Strauss H . Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2005; 91(2):498-505. DOI: 10.1210/jc.2005-1534. View

Are C, Hsu J, Ghossein R, Schoder H, Shah J, Shaha A . Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol. 2007; 14(11):3210-5. DOI: 10.1245/s10434-007-9531-4. View

Branstetter 4th B, Blodgett T, Zimmer L, Snyderman C, Johnson J, Raman S . Head and neck malignancy: is PET/CT more accurate than PET or CT alone?. Radiology. 2005; 235(2):580-6. DOI: 10.1148/radiol.2352040134. View

Wadsak W, Mitterhauser M . Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010; 73(3):461-9. DOI: 10.1016/j.ejrad.2009.12.022. View

Seo J, Lee S, Ahn B, Lee J . Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf). 2009; 72(4):558-63. DOI: 10.1111/j.1365-2265.2009.03693.x. View

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

Lloyd R, Erickson L, Casey M, Lam K, Lohse C, Asa S . Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004; 28(10):1336-40. DOI: 10.1097/01.pas.0000135519.34847.f6. View

Chin B, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P . Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004; 89(1):91-5. DOI: 10.1210/jc.2003-031027. View

Newberg A, Alavi A, Reivich M . Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med. 2002; 32(1):13-34. DOI: 10.1053/snuc.2002.29276. View

10.

Gough J, Scott-Coombes D, Palazzo F . Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg. 2008; 32(7):1264-8. DOI: 10.1007/s00268-008-9503-2. View

11.

Bogsrud T, Karantanis D, Nathan M, Mullan B, Wiseman G, Collins D . The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun. 2007; 28(5):373-81. DOI: 10.1097/MNM.0b013e3280964eae. View

12.

Kim J, Ryu J, Kim T, Kim W, Kwon G, Gong G . 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab. 2007; 92(5):1630-4. DOI: 10.1210/jc.2006-2311. View

13.

Gemsenjager E, Perren A, Seifert B, Schuler G, Schweizer I, Heitz P . Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003; 197(2):182-90. DOI: 10.1016/S1072-7515(03)00421-6. View

14.

Razfar A, Branstetter 4th B, Christopoulos A, LeBeau S, Hodak S, Heron D . Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2010; 136(2):120-5. DOI: 10.1001/archoto.2009.215. View

15.

Pryma D, Schoder H, Gonen M, Robbins R, Larson S, Yeung H . Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006; 47(8):1260-6. View

16.

Liu Y . Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography. Ann Nucl Med. 2009; 23(1):17-23. DOI: 10.1007/s12149-008-0198-0. View

17.

Esteva D, Muros M, Llamas-Elvira J, Jimenez Alonso J, Villar J, Lopez de la Torre M . Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. Ann Surg Oncol. 2009; 16(7):2006-13. DOI: 10.1245/s10434-009-0483-8. View

18.

FEINE U, Lietzenmayer R, Hanke J, Held J, Wohrle H, Muller-Schauenburg W . Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996; 37(9):1468-72. View

19.

Sebastianes F, Cerci J, Zanoni P, Soares Jr J, Chibana L, Tomimori E . Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2007; 92(11):4485-8. DOI: 10.1210/jc.2007-1043. View

20.

Law T, Lang B . Incidental thyroid carcinoma by FDG-PET/CT: a study of clinicopathological characteristics. Ann Surg Oncol. 2010; 18(2):472-8. PMC: 3032177. DOI: 10.1245/s10434-010-1287-6. View